Last reviewed · How we verify

NCT03679156

Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor

Completed Last updated 20 September 2018
What this trial tests

trial testing OCT in Neovascular Age-related Macular Degeneration in 18 participants. Completed in 15 April 2017.

Timeline
30 May 2016
Primary endpoint
2 November 2016
15 April 2017

Quick facts

Lead sponsorHospital Hietzing
StatusCompleted
Study typeOBSERVATIONAL
Enrollment18
Start date30 May 2016
Primary completion2 November 2016
Estimated completion15 April 2017

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Hietzing

Who can join

Adults 66 to 98, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: To assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis. Methods: 18 patients (18 eyes) with neovascular AMD were recruited subsequent to completion the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range: 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as-needed \[pro re nata (PRN)\]. Functional and morphological changes were assessed using spectral domain optical coherence tomography (SD-OCT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of OCT

Trials testing the same drug.

Other recruiting trials for Neovascular Age-related Macular Degeneration

Currently open trials in the same condition.

Other Hospital Hietzing trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03679156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing